Lumakras (sotorasib tablets - Amgen) — Cigna

Initial criteria

• Patient age ≥ 18 years
• Patient has advanced or metastatic disease
• Patient has KRAS G12C mutation-positive disease
• Medication is used in combination with Erbitux (cetuximab intravenous infusion) or Vectibix (panitumumab intravenous infusion) OR patient is unable to tolerate combination therapy
• Patient has previously received a chemotherapy regimen for colon or rectal cancer

Approval duration

1 year